NEW YORK (360Dx) – Seeking FDA approval for its complete blood count (CBC) toolkit, startup Essenlix aims to address the costs and challenges of CBC assays in the clinical space with its smartphone-based instant mobile self-test (iMOST) technology.
NEW YORK (360Dx) – Seeking FDA approval for its complete blood count (CBC) toolkit, startup Essenlix aims to address the costs and challenges of CBC assays in the clinical space with its smartphone-based instant mobile self-test (iMOST) technology.
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.